Colletofragarone A2 Inhibits Cancer Cell Growth


Journal

Chemical research in toxicology
ISSN: 1520-5010
Titre abrégé: Chem Res Toxicol
Pays: United States
ID NLM: 8807448

Informations de publication

Date de publication:
19 09 2022
Historique:
pubmed: 27 8 2022
medline: 21 9 2022
entrez: 26 8 2022
Statut: ppublish

Résumé

Mutant p53 not only loses its original tumor suppressor function but also acquires new abilities regarding oncogenic progression. Therefore, the strategy of targeting mutant p53 has attracted attention for cancer therapy. We isolated colletofragarone A2 (CF) from the fungus

Identifiants

pubmed: 36027604
doi: 10.1021/acs.chemrestox.2c00202
doi:

Substances chimiques

Cycloheximide 98600C0908
DNA 9007-49-2
Molecular Chaperones 0
Tumor Suppressor Protein p53 0
colletofragarone A2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1598-1603

Auteurs

Yusaku Sadahiro (Y)

Department of Natural Medicines, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto862-0973, Japan.

Yuki Hitora (Y)

Department of Natural Medicines, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto862-0973, Japan.

Ichiro Kimura (I)

Department of Natural Medicines, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto862-0973, Japan.

Natsuko Hitora-Imamura (N)

Department of Natural Medicines, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto862-0973, Japan.

Risako Onodera (R)

Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto862-0973, Japan.

Keiichi Motoyama (K)

Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto862-0973, Japan.

Sachiko Tsukamoto (S)

Department of Natural Medicines, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto862-0973, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH